NCT05083169 2026-03-18MajesTEC-3Janssen Research & Development, LLCPhase 3 Active not recruiting587 enrolled 1 FDA
NCT03180736 2025-12-19EMN14European Myeloma Network B.V.Phase 3 Completed304 enrolled 19 charts 1 FDA
NCT01998971 2025-04-25A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaJanssen Research & Development, LLCPhase 1 Completed240 enrolled 2 FDA